newsfilter
← Latest News
GlobeNewswire·

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and